Novel imipridone combination therapies targeting oncohistone H3K27M mutant diffuse midline glioma (DMG)

被引：0
|
作者：
Borsuk, Robyn [1 ]
Zhou, Lanlan [2 ,3 ,4 ,5 ,6 ]
Lulla, Rishi [1 ]
El-Deiry, Wafik [2 ,3 ,4 ,5 ,6 ]
机构：
[1] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA
[2] Brown Univ, Joint Program Canc Biol, Providence, RI 02912 USA
[3] Lifespan Canc Inst, Providence, RI USA
[4] Brown Univ, Dept Pathol & Lab Med, Providence, RI 02912 USA
[5] Lifespan, Dept Med, Hematol Oncol Div, Providence, RI USA
[6] Brown Univ, Providence, RI 02912 USA
来源：
CANCER RESEARCH | 2020年 / 80卷 / 16期
关键词：
D O I：
10.1158/1538-7445.AM2020-5407
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5407
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A case of diffuse midline glioma, H3 K27M-mutant
    Kyriakopoulos, G.
    Anagnostopoulos, C.
    Boskos, C.
    Korfias, S.
    Stranjalis, G.
    Razis, E.
    Argyrakos, T.
    VIRCHOWS ARCHIV, 2017, 471 : S219 - S219
  • [22] Synergistic imipridone-based drug combinations for treatment of pediatric H3K27M mutant diffuse intrinsic pontine glioma (DIPG)
    Borsuk, Robyn
    Zhou, Lanlan
    Zheng, Yiqun
    Prabhu, Varun
    Allen, Joshua
    Tapinos, Nikos
    Lulla, Rishi
    Wafik, El-Deiry
    FASEB JOURNAL, 2021, 35
  • [23] A LONG PEPTIDE VACCINE TARGETING THE CLONAL DRIVER MUTATION H3K27M IN ADULT PATIENTS WITH DIFFUSE MIDLINE GLIOMA
    Grassl, N.
    Poschke, I.
    Lindner, K.
    Kromer, K.
    Bunse, L.
    Denberger, I. Mil
    Jaehne, K.
    Haltenhof, G.
    Tan, C.
    Green, E.
    Kessler, T.
    Suwala, A.
    Sahm, F.
    Eisele, P.
    Breckwoldt, M.
    Vajkoczy, P.
    Grauer, O.
    Herrlinger, U.
    Tonn, J.
    Denk, M.
    Bendszus, M.
    von Deimling, A.
    Winkler, F.
    Wick, W.
    Lindner, J.
    Platten, M.
    Sahm, K.
    NEURO-ONCOLOGY, 2023, 25 : 1 - 1
  • [24] Candidate differentiation stall in epithelial mesenchymal transition in H3K27M diffuse midline glioma
    Cheney, Allison R.
    Sanders, Lauren M.
    Seninge, Lucas
    Beale, Holly C.
    Kephart, Ellen Towle
    Pfeil, Jacob
    Learned, Katrina
    Lyle, A. Geoffrey
    Bjork, Isabel
    Haussler, David
    Salama, Sofie R.
    Vaske, Olena M.
    CANCER RESEARCH, 2020, 80 (14) : 83 - 83
  • [25] New Developments in the Pathogenesis, Therapeutic Targeting, and Treatment of H3K27M-Mutant Diffuse Midline Glioma
    Argersinger, Davis P.
    Rivas, Sarah R.
    Shah, Ashish H.
    Jackson, Sadhana
    Heiss, John D.
    CANCERS, 2021, 13 (21)
  • [26] Diffuse Midline Glioma, H3 K27M-Mutant: A Case Report
    Rodriguez Leon, Jose
    Perez Berenguer, Juan
    Morales Vargas, Bryan
    Rivera Roman, Keila
    Vigo Prieto, Juan
    Labat Alvarez, Eduardo
    Ferrer Torres, Luis
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2018, 150 : S34 - S34
  • [27] The prognosis of diffuse midline glioma H3 K27M mutant.
    Kim, Donghwan
    Chung, Chun Kee
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [28] Clinicopathological analysis of diffuse midline glioma, H3 K27M-mutant
    Kim, Seong-Ik
    Lee, Yujin
    Won, Jae Kyung
    Park, Sung-Hye
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2017, 76 (06): : 517 - 517
  • [29] REVERTANCE OF THE H3K27M MUTATION RESCUES CHROMATIN MARKS NECESSARY FOR ONCOGENESIS IN DIFFUSE MIDLINE GLIOMA
    Nesvick, Cody
    Day, Charles
    Zhang, Liang
    Hinchcliffe, Edward
    Daniels, David
    NEURO-ONCOLOGY, 2020, 22 : 302 - 302
  • [30] Pediatric Diffuse Midline Glioma with Concurrent H3K27M and BRAFV600E Mutations
    Oon, M.
    Tan, C.
    JOURNAL OF PATHOLOGY, 2023, 261 (SUPPL1): : S67 - S67
12345